45 GyRBE for group III orbital embryonal rhabdomyosarcoma
- PMID: 31530120
- DOI: 10.1080/0284186X.2019.1627412
45 GyRBE for group III orbital embryonal rhabdomyosarcoma
Abstract
Purpose: Despite widespread concerns of radiotherapy toxicity in children with head and neck tumors, recent Children's Oncology Group (COG) findings suggest that the use of 45 Gy results in an unacceptably high rate of local recurrences in patients with low-risk orbital rhabdomyosarcoma. We therefore evaluated outcomes in our pediatric patients who received 45 GyRBE using proton therapy. Material and methods: To assess disease control and toxicity, we reviewed the medical records of 30 children (≤21 years old) with COG stage 1, group III embryonal orbital rhabdomyosarcoma enrolled on a prospective outcome study and treated with proton therapy between 2007 and 2018. Results: Median age at the time of radiation was 4.8 years old. Twenty-one and nine patients received ifosfamide- and cyclophosphamide-based chemotherapy according to their respective cooperative group regimens. Median duration between the start of induction chemotherapy and radiation was 12 weeks. Two patients had a complete response to induction chemotherapy and two had stable disease. Twenty-six patients had a partial response to induction chemotherapy, with a median volume reduction of 66%. With a median follow-up of 4.0 years (range, 0.5-9.5 years), we observed 1 local failure 6 months following treatment in a patient who had a partial response to cyclosphophomide-based induction chemotherapy. The 5-year local control, progression-free survival, and overall survival rates were 97%, 97%, and 100%, respectively. Serious late toxicities included 18 patients with cataracts, 4 with exposure keratoconjunctivitis resulting in permanently reduced visual acuity, and 1 with chronic sinusitis. Conclusion: 45 GyRBE offers effective local control for most patients with group III orbital rhabdomyosarcoma. The delivery of proton therapy to the postinduction tumor volume plus a small margin can mitigate early- and intermediate-term toxicity, but side effects still occur and long-term data are needed to demonstrate the dosimetric advantage of proton therapy.
Similar articles
-
Dose-Effect Analysis of Early Changes in Orbital Bone Morphology After Radiation Therapy for Rhabdomyosarcoma.Pract Radiat Oncol. 2020 Jan-Feb;10(1):53-58. doi: 10.1016/j.prro.2019.10.002. Epub 2019 Oct 16. Pract Radiat Oncol. 2020. PMID: 31629089
-
Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma.Int J Radiat Oncol Biol Phys. 2021 Mar 1;109(3):718-725. doi: 10.1016/j.ijrobp.2020.09.050. Int J Radiat Oncol Biol Phys. 2021. PMID: 33516439
-
Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide.Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1151-1157. doi: 10.1016/j.ijrobp.2018.11.049. Epub 2018 Nov 30. Int J Radiat Oncol Biol Phys. 2019. PMID: 30508617 Free PMC article.
-
Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas.Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1294-9. doi: 10.1016/s0360-3016(02)04290-6. Int J Radiat Oncol Biol Phys. 2003. PMID: 12654440 Review.
-
[Orbital rhabdomyosarcoma: difficulties with European treatment protocol].Arch Soc Esp Oftalmol. 2005 Jun;80(6):331-8. doi: 10.4321/s0365-66912005000600006. Arch Soc Esp Oftalmol. 2005. PMID: 15986273 Review. Spanish.
Cited by
-
Clinical Insight on Proton Therapy for Paediatric Rhabdomyosarcoma.Cancer Manag Res. 2023 Oct 10;15:1125-1139. doi: 10.2147/CMAR.S362664. eCollection 2023. Cancer Manag Res. 2023. PMID: 37842128 Free PMC article. Review.
-
Efficacy and safety of proton beam therapy for rhabdomyosarcoma: a systematic review and meta-analysis.Radiat Oncol. 2023 Feb 20;18(1):31. doi: 10.1186/s13014-023-02223-6. Radiat Oncol. 2023. PMID: 36805784 Free PMC article. Review.
-
Proton Radiotherapy to Reduce Late Complications in Childhood Head and Neck Cancers.Int J Part Ther. 2021 Jun 25;8(1):155-167. doi: 10.14338/IJPT-20-00069.1. eCollection 2021 Summer. Int J Part Ther. 2021. PMID: 34285943 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical